Understanding and targeting bone marrow microenvironment in myelofibrosis

了解和靶向骨髓纤维化中的骨髓微环境

基本信息

  • 批准号:
    10321224
  • 负责人:
  • 金额:
    $ 57.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-01 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Project summary/Abstract Understanding and targeting abnormal tumor microenvironment is critically important for developing effective therapy. Primary myelofibrosis (PMF) is a form of myeloproliferavtie neoplasm (MPN) that often progresses to lethal leukemia. Treatment options are limited for PMF, and the only potential cure, stem cell transplantation, is prohibitively toxic for most patients. Thus, novel and effective therapies are in great need for PMF. Recurrent mutations resulting in abnormal activation of the JAK-STAT pathway have been shown to be the driver of the disease. As a result, JAK inhibitors have been developed to treat PMF. However, these inhibitors only reduce some constitutional symptoms without significant impact on disease-causing leukemia stem cells (LSCs). A deeper understanding of the pathogenesis of PMF will offer the opportunity to better treat the disease. The bone marrow niche is a critical component to the pathogenesis of PMF. Our preliminary data show that bone marrow LepR+ stromal cells are the source of fibrosis. We have also identified several key mediators of LepR+ cell fibrosis. In this proposal, we propose to elucidating the cellular and molecular mechanisms of how LSCs interact with the fibrotic niche in vivo. We will test whether targeting the fibrosis mediators will lead to efficient elimination of LSCs and have synergistic effects with JAK inhibitors. By having a deeper understanding of the interaction between LSCs and the niche, our strategy of targeting the diseased niche may provide novel therapeutics to PMF.
项目摘要/摘要 了解和靶向异常的肿瘤微环境对于制定有效的治疗方案至关重要 心理治疗。原发性骨髓纤维化(PMF)是一种骨髓增生性肿瘤(MPN),通常进展为 致命性白血病。PMF的治疗选择有限,唯一潜在的治愈方法是干细胞移植。 对大多数患者来说毒性太大了。因此,PMF迫切需要新的有效的治疗方法。复发性 导致JAK-STAT通路异常激活的突变已被证明是导致 疾病。因此,JAK抑制剂被开发出来用于治疗PMF。然而,这些抑制物只会减少 一些体质症状对致病白血病干细胞(LSCs)无明显影响。一个 对PMF发病机制的深入了解将为更好地治疗该病提供机会。这个 骨髓微环境是PMF发病机制中的重要组成部分。我们的初步数据显示骨头 骨髓Lepr+间质细胞是纤维化的来源。我们还确定了LEPR+的几个关键调节因子 细胞纤维化。在这项建议中,我们建议阐明LSCs的细胞和分子机制 在体内与纤维化的壁龛相互作用。我们将测试以纤维化介质为目标是否会导致有效 消除LSCs,并与JAK抑制剂有协同作用。通过更深入地了解 LSC与生态位之间的相互作用,我们针对患病生态位的策略可能会提供新的 治疗学到PMF。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lei Ding其他文献

Lei Ding的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lei Ding', 18)}}的其他基金

Developing Next Generation Genetics for Understanding Hematopoietic Stem Cell Biology
开发下一代遗传学以了解造血干细胞生物学
  • 批准号:
    10898485
  • 财政年份:
    2022
  • 资助金额:
    $ 57.51万
  • 项目类别:
Developing Next Generation Genetics for Understanding Hematopoietic Stem Cell Biology
开发下一代遗传学以了解造血干细胞生物学
  • 批准号:
    10710163
  • 财政年份:
    2022
  • 资助金额:
    $ 57.51万
  • 项目类别:
Understanding and targeting bone marrow microenvironment in myelofibrosis
了解和靶向骨髓纤维化中的骨髓微环境
  • 批准号:
    10543555
  • 财政年份:
    2021
  • 资助金额:
    $ 57.51万
  • 项目类别:
Understanding the role of stellate cells in the liver hematopoietic stem cell niche
了解星状细胞在肝脏造血干细胞生态位中的作用
  • 批准号:
    10666495
  • 财政年份:
    2020
  • 资助金额:
    $ 57.51万
  • 项目类别:
Understanding the role of stellate cells in the liver hematopoietic stem cell niche
了解星状细胞在肝脏造血干细胞生态位中的作用
  • 批准号:
    10191033
  • 财政年份:
    2020
  • 资助金额:
    $ 57.51万
  • 项目类别:
Understanding the role of stellate cells in the liver hematopoietic stem cell niche
了解星状细胞在肝脏造血干细胞生态位中的作用
  • 批准号:
    10034524
  • 财政年份:
    2020
  • 资助金额:
    $ 57.51万
  • 项目类别:
Understanding the role of stellate cells in the liver hematopoietic stem cell niche
了解星状细胞在肝脏造血干细胞生态位中的作用
  • 批准号:
    10449115
  • 财政年份:
    2020
  • 资助金额:
    $ 57.51万
  • 项目类别:
Regulation of hematopoietic stem cells and leukemia stem cells by thrombopoietin
血小板生成素对造血干细胞和白血病干细胞的调节
  • 批准号:
    9895854
  • 财政年份:
    2016
  • 资助金额:
    $ 57.51万
  • 项目类别:
Regulation of hematopoietic stem cells and leukemia stem cells by thrombopoietin
血小板生成素对造血干细胞和白血病干细胞的调节
  • 批准号:
    9242049
  • 财政年份:
    2016
  • 资助金额:
    $ 57.51万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 57.51万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 57.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 57.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 57.51万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 57.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 57.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 57.51万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 57.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 57.51万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 57.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了